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Recent reviews continue to emphasize the high
mortality associated with the syndrome of acute
renal failure (ARF) [11. When Bywaters and Beall
described ARF in 1941, the mortality of their pa-
tients was greater than 90% [2, 3]. During the Kore-
an and Vietnamese wars, mortality from ARF fell to
between 40 and 50% [4, 5]. Mortality rates in most
civilian or nonmilitary reports vary between 20 and
40%, depending on the prevalence of surgical and
trauma patients in whom mortality is higher than
those with nonsurgical causes, such as toxins, myo-
cardial infarction, and sepsis. In our own experi-
ence at the Royal Prince Alfred Hospital from 1968
to 1976, 89 patients underwent acute dialysis for
ARF. The mortality rate was 54% in surgical pa-
tients and 52% in medical patients. These numbers
include only those patients who required hemo-
dialysis.
Definition and classification of ARE
The syndrome of ARF may be defined as follows:
an acute failure of the function of the kidney that
may lead to disturbances in fluid and electrolyte bal-
ance, acid-base homeostasis, hemopoiesis and clot-
ting mechanisms, and endocrine function. These
disturbances may produce in the patient: (a) gener-
alized ill health, (b) anorexia, nausea, and vomiting,
(c) symptoms and signs of fluid imbalance, (d) easy
bleeding and bruising, and (e) tremor, asterixis,
confusion, and coma. From this definition it is ap-
parent that ARF includes virtually all functional dis-
turbances of the kidney except those that are chron-
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ic in nature. Such a broad definition is desirable,
because it emphasizes, first, that multiple etiologies
are involved and, second, that the syndrome affects
many separate functions of the kidney. In fact, the
diagnosis of ARF should be considered incomplete
unless the definite etiologic factor, or at least the
most likely one, is specified. Although it has been
convenient in the past to consider so-called surgical
cases as one subgroup and medical cases as anoth-
er, it is becoming increasingly apparent that more
specific causes should be stated, particularly in rela-
tion to prognosis and drug therapy. As an example,
ARF induced by urographic radiocontrast drugs (as
discussed elsewhere in the Symposium) is far mild-
er than it is when caused by many other nephrotox-
ins, such as mercuric chloride.
It has also been customary to divide etiologic fac-
tors into the three categories of prerenal, renal, and
postrenal. The latter refers to obstruction of the uri-
nary tract and will not be considered here, other
than to emphasize its diagnostic importance. The
vast majority of cases of ARF are associated with
oliguria or anuria. In some circumstances, how-
ever, urine volume may be either normal or in-
creased. This is most commonly seen in cases of
ARF that are initially oliguric but then proceed
through a diuretic phase during recovery. Less
commonly, depending on etiology, polyuria may be
prominent from the beginning [6, 7].
Various terms have been used synonymously
with ARF. These include "acute tubular necrosis"
(often when this pathologic lesion is not present),
"acute intrinsic renal failure," and an old term
"vaso-motorische nephrose," which has been re-
vived as vasomotor nephropathy." Under some
circumstances, these terms are potentially mis-
leading, and the more general term, ARF, is pre-
ferred.
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Patho genesis of ARF
In most patients, the etiology is complex but can
be divided, for the sake of discussion, into two
areas —the effect of ischemia and the effect of neph-
rotoxins.
Ischernia. Hypotension following trauma, blood
loss, myocardial infarction, or septicemia accounts
for most instances of ARF in the intensive care situ-
ation, and many experimental models have been de-
vised to mimic this [8—10]. Glycerol-induced renal
failure [11] is thought to produce ARF in experi-
mental animals by a reduction in blood volume
(thus mimicking hemorrhage) and by the production
of myohemoglobinuria, similar to that seen with
crush injuries in man. Direct interference with the
renal blood supply in patients with aortic aneu-
rysms, renal artery surgery, and renal transplanta-
tion is mirrored closely by the experimental model
of renal artery occlusion [8, 12]. Clamping the main
renal artery for periods of 30 to 60 mm, or partially
clamping the vessels for up to 4 hours, has pro-
duced ischemic damage to the kidney similar to that
seen in man [10, 12]. The infusion of norepinephrine
into the renal arteries also produces ischemic dam-
age [13]. Under controlled circumstances, the de-
gree of damage is proportional to the duration of the
infusion. In this experimental model, no consistent
pattern of pathologic change is observed [13].
Renal damage from ischemia is usually consid-
ered in relation to changes in the general circulation
that reduce renal blood flow. It is also possible,
however, that the intrarenal circulation may be pri-
marily compromised, both by lesions of the main
renal vessels as well as by lesions of the glomerular
capillaries. It has also been postulated that in some
situations, the postglomerular microcirculation may
be affected [14, 15].
Nephrotoxins. The term is used in its most gener-
al sense to include poisons, chemicals, drugs, and
natural products. These range from "bee sting to
bismuth, from snake bite to sulfonamides" [16]. In
many instances, the effect of the nephrotoxin is
dose related, but in others, particularly in clinical
situations, the absence of such a relationship sug-
gests that immunologic or other mechanisms are op-
erating.
The standard experimental models for toxic renal
failure in animals use mercuric chloride or uranyl
nitrate [8, 17—19]. Toxins have diverse effects. In
some models, renal vasoconstriction is an initial
event, but in others, vasoconstriction does not ap-
pear to be responsible for the observed changes in
renal blood flow. In addition, alterations in renal
blood flow do not necessarily correlate with the de-
gree of renal impairment induced by the toxin.
Thus, some "nephrotoxic" models are similar to
"ischemic" models, whereas other are not. Tubular
obstruction may also play a role in the mercuric
chloride model in the rat [8]. In some experiments,
deposition of crystals causes intraluminal obstruc-
tion [20, 21]. In acute uric acid nephropathy, the
syndrome of ARF may result from crystal deposi-
tion. In contrast, tubular obstruction appears to be
relatively unimportant in uranyl nitrate model [18,
19]. It is also possible that the rate of glomerular
filtration might be compromised by the direct effect
of a nephrotoxin on the permeability of the gb-
merular membrane. Changes in ultrafiltration coef-
ficients (Kt) have been demonstrated in both is-
chemic and toxic models of ARF [8, 14].
In man, a combination of ischemia and nephro-
toxins is probably the most common cause of ARF,
because hypotension so often accompanies those
situations in which a nephrotoxic agent is involved.
It is not the purpose of this review to consider the
experimental pathophysiology of ARF in detail.
The field is admirably summarized by Stein, Lif-
schitz, and Barnes [8] and in a symposium [22]. Cer-
tain points, however, warrant emphasis, because of
their implication for drug therapy. In the standard
animal models—glycerol, renal artery occlusion,
norepinephrine, uranyl nitrate, and mercuric chlo-
ride—the major manifestations of ARF are oliguria
and evidence of reduced glomerular filtration.
There are four principal underlying mechanisms
that may account for these manifestations: a per-
sistent reduction in renal blood flow, a reduction in
the coefficient of filtration at the glomerulus, tubular
obstruction, and excessive back leakage (reabsorp-
tion) across the tubule. These are accompanied by
morphologic correlates that include variable lesions
of the tubular epithelium and abnormal thickening
of the glomerular membranes. The first three fac-
tors might readily produce a true reduction in gb-
merubar filtration. With the fourth factor of exces-
sive back leakage, measurements of GFR might be
inaccurate, however. Specifically, if the selective
permeability of the tubular epithelium were so im-
paired that the solutes used as gbomerular markers
(for example, inulin) were reabsorbed from the
tubular fluid and hence not excreted in the urine,
measured GFR might be falsely low. It is technical-
ly difficult to determine to what degree this occurs
[19]. In experimental models, tubular permeability
to glomerular markers probably varies with the
etiology and severity of ARF and also with the du-
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ration of the insult. In many clinical counterparts, it
is not possible to evaluate the relative importance of
these underlying mechanisms. In addition, as dis-
cussed elsewhere in this Symposium, there are
many clinical situations that are not encompassed
by these experimental models. For example, in
aminoglycoside nephrotoxicity, the biochemical
mechanisms appear to be highly specific for that
class of compounds.
In many models of established ARF, renal blood
flow may return to normal or to even elevated val-
ues, whereas evidence of diminished filtration per-
sists. If this generalization is correct, it follows that
in order to be effective in ARF, a drug would have
to act at the level of glomerular permeability, tubu-
lar obstruction, or tubular permeability, or be able
to prevent an initial fall in renal blood flow. Once
ARF is established, those drugs that have a primary
vasomotor action might be relatively ineffective in
altering the natural history of the syndrome.
Pharmacologic intervention in ARF
For purposes of this discussion, one may distin-
guish two separate but related goals of therapy. The
first involves those measures that are directed to the
general well-being of the patient, in order to mini-
mize morbidity and mortality, and thereby enable
the patient to survive for a sufficiently long time for
the renal lesion to be repaired. The second involves
those measures directed to the prevention and/or
correction of the renal lesion itself.
Under the first category, one might further sub-
divide therapeutic measures into two parts: those
related to the pathogenesis of ARF and those re-
lated to its sequelae. With hemorrhagic hypotension
as an example, vigorous treatment with parenteral
fluids, plasma, or whole blood would be obviously
indicated early in the patient's course, but once
ARF had established itself, such parenteral fluid
therapy should be carefully monitored and the regi-
men determined in large part by the then prevailing
excretory function of the kidney. Once ARF has be-
come established, the regulatory or homeostatic
functions of the kidney are the principal victims.
The most obvious expression of this catastrophe in-
volves urine formation. Whether output is oliguric
or polyuric, it becomes fixed by the disease and no
longer responds to the metabolic needs of the pa-
tient. In a less obvious manner, the nonexcretory
functions of the kidney (circulatory, hormonal, and
so forth) may also lose their regulatory efficiency.
Proper therapy minimizes the metabolic derange-
ments related to fluid and electrolyte balance,
anemia, acid-base balance, hyperkalemia, and ca-
loric intake. In large measure, such therapy in-
volves the regulation of intake, either oral or par-
enteral, although, to a very limited extent, urinary
output may be modified by the use of diuretic
agents. The proper use of dialysis is also involved.
These aspects of the management of ARF are well
covered elsewhere [23, 24] and will not be consid-
ered further.
In the second category of therapy, we wish to
consider those pharmacologic agents that are spe-
cifically designed to influence the course of the re-
nal lesion. The subdivision between prophylaxis
and treatment is somewhat artificial, and there are
many instances of overlap.
Drugs used in prevention of ARF
For adequate prevention, it is essential to have a
high index of suspicion in those circumstances in
which ARF may be an anticipated complication.
(I) Alkalinizing agents. As a general rule, organ-
ic acids (such as drugs or their metabolites) are
more soluble in aqueous solution in the form of their
salts than as the undissociated acid. If solubility is
exceeded, they precipitate. If this occurs within the
tubular lumen, it may produce ARF. For this rea-
son, the urine is purposefully alkalinized as a pro-
phylactic measure. Sodium bicarbonate is the agent
of choice and is most commonly used, although on
theoretical grounds, acetazolamide might also be ef-
fective. The reverse situation holds true for drugs
that are organic bases (that is, drugs that have a
higher solubility at an acid pH). These, however,
are administered in such small amounts that solubil-
ity is not exceeded, and there are no known ex-
amples for which the urine should be acidified for
this purpose. In the case of organic acids, it should
be emphasized that alkalinization of the urine may
accomplish two separate goals—either to increase
urinary solubility or to increase the rate of urinary
excretion. The latter effect is seen with compounds
such as salicylate and other lipid soluble acids, but
it is not involved in the present situation.
Alkalinization of the urine was used with the rela-
tively insoluble sulfonamides. The same principles
underlie the management of cystinuria, a metabolic
defect in which the excessive cystine in the urine
may be kept in solution at a high pH. In the treat-
ment of acute leukemia, methotrexate was initially
used in doses of 1 to 5 mg/rn2 of body surface area,
and it was then demonstrated that intermittent ther-
apy with parenteral doses of 30 mg/m2 improved
survival [25]. Even larger doses, between 3,000 and
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18,000 mg/rn2 combined with folinic acid rescue,
have been used in some instances. Excretion of
methotrexate is predominantly renal, and at high
concentrations its renal clearance is constant and
exceeds that of inulin. It is a dicarboxylic acid with
pKa's of 4.8 and 5.7 and is relatively insoluble in an
acid urine [20, 21]. The cause of methotrexate neph-
rotoxicity is probably precipitation of the drug in
the renal tubules. Other suggestions include a neph-
rotoxic action related to 7-hydroxymethotrexate
that may represent up to 30% of the total drug in the
urine, and is only 25% as soluble as methotrexate
itself. The high dose of folinic acid used in the res-
cue has also been implicated in the development of
nephrotoxicity. The prevention of ARF involves
maintaining an adequate degree of hydration, so
that urine output remains high; draining of any fluid
collection such as a pleural effusion prior to drug
administration, so that the drug does not become
sequestered; and alkalinization with sodium bi-
carbonate to maintain the urine pH between 7 and
7.5, commencing 12 hours before administration of
the drug. Using this approach, Pitman et al [26]
were able to keep nephrotoxicity to a minimum. It
should be emphasized that the urine must be alka-
line at the time of the administration of methotrex-
ate. This should be monitored with an accurately
determined pH on a sample of urine voided immedi-
ately prior to the drug ingestion. In addition, drug
solubility is many times greater at pH 7.5 than at pH
7; there is considerable individual variation in the
amount of sodium bicarbonate required to achieve
the optimal and maximal pH. If ARF were to devel-
op in association with anuria, nothing would be
gained by continued administration of sodium bi-
carbonate.
(2) Agents that increase the rate of urine flow.
There are many examples in which protection
against nephrotoxicity appears to be achieved by
the maintenance of a high rate of urine flow. It is
generally believed that the mechanism involves
keeping the urine dilute so that the tubular cells are
not exposed to an exceedingly high concentration of
the putative nephrotoxin in the tubular fluid. It is
possible, however, that other renal mechanisms (for
example, those acting on the renin-angiotensin sys-
tem) might also be involved. In many studies, both
oral and parenteral fluids have provided protection.
In the severely ill patient, particularly with hypo-
tension, correction of the underlying cause and res-
toration of normal blood pressure must accompany
or precede any attempt to increase urine flow rate
with osmotic or diuretic agents.
Cis-Platinum (II) diaminedichioride is a drug
which is used in the treatment of various neo-
plasias, especially embryonal cell carcinoma of the
testis. The most important and dose-limiting ad-
verse effect is its nephrotoxicity [27—29], which is
usually reversible. Pathologic changes appear to be
most prominent in the distal convoluted tubules and
collecting ducts, with only slight involvement of the
proximal tubule [28, 29]. Cellular atypia suggests
that cis-platinum is directly toxic to the renal tubu-
lar cells. Nephrotoxicity and ARF can be amelio-
rated without interfering with the antineoplastic ac-
tion of the drug. This involves the maintenance of a
high rate of urine flow prior to and during the ad-
ministration of the drug. Adequate hydration may
sometimes be sufficient, or mannitol and furose-
mide may be required [29]. The toxic action of the
drug does not appear to be pH dependent, and the
specific cause of the tubular necrosis is obscure.
The mortality in patients who develop ARF follow-
ing surgery for leaking abdominal aortic aneurysms
remains very high, being from 80 to 90% in most
series [35]. This is an example of renal ischemia that
is comparable in many ways to the experimental
models referred to above [8—10, 12, 13]. With con-
temporary surgical techniques and with hypother-
mia and adequate oxygenation, ARF is largely pre-
ventable. It is commonplace to provide adequate in-
take of fluids, including mannitol, prior to many
types of vascular surgery [36]. Although it is clear
that mannitol increases the rate of urine flow, it is
not definite that it offers advantage over adequate
hydration [1, 13, 37].
There are a number of other situations in which it
is worthwhile to alkalinize the urine, or increase the
rate of flow, or both. Unlike the examples cited im-
mediately above, it is often not possible to predict
the exact time at which the kidney will be subjected
to potential damage. Hence, in these conditions,
these measures become a mixture of prophylaxis
and treatment. The clinical conditions involve myo-
globinuria from both traumatic and nontraumatic
rhabdomyolysis, hemoglobinuria from a variety of
causes including transfusion reactions, and acute
uricosuria from causes less predictable than cancer
chemotherapy [11, 33]. In most circumstances,
there is no evidence to support the use of mannitol
over adequate hydration.
Among the many causes of rhabdomyolysis,
there is little opportunity for specific prophylaxis,
with one possible exception. This involves the sug-
gestion that the correction of severe potassium de-
pletion, which experimentally predisposes to
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muscle necrosis and subsequent renal failure [34],
may prevent such an occurrence in man.
(3) Agents that reduce urate production and ex-
cretion. The first cases of uric acid nephropathy in
the clinical setting of the treatment for leukemia or
lymphoma were reported in 1929 [30]. Recent re-
views [31, 32] have pointed out that this form of
ARF is preventable. There is good evidence to sup-
port the following sequence of events: tumor or
cell destruction; hyperuricemia; acute increase in
the amount of urate filtered at the glomeruli and/or
secreted into the tubular fluid; and precipitation of
uric acid from an excessively high concentration. If
this latter occurs within the tubular fluid, it leads to
intratubular obstruction. Precipitation may also oc-
cur at more distal sites, leading to uric acid crystal-
luria and crystal deposition. This may cause ure-
teral obstruction. Although a high concentration of
urate also develops within the renal parenchyma, its
significance is not clear, at least as far as the patho-
genesis of ARF is concerned. In some patients with
acute hyperuricemia, there is also an acute hyper-
phosphatemia as a result of cell breakdown. This
increases the amount of phosphate delivered to the
tubule and may lead to the precipitation of both
phosphate and uric acid [32].
Although the precipitation of uric acid can be di-
minished by the maintenance of urine flow and a
high urinary pH (as above), these measures are in-
adequate in the face of the extreme hyperuricemia
that accompanies the treatment of leukemia or lym-
phoma. Allopurinol, which blocks urate formation,
should be used as a prophylactic agent. Therapy
should commence as soon as the decision is made to
proceed with either chemotherapy or radiotherapy
of the underlying disease, and doses in excess of the
minimal 300 mgm/day may be required. The plasma
urate should be reduced to subnormal values prior
to the start of antineoplastic treatment. Even if
there is mild renal impairment, allopurinol treat-
ment should be maintained. There is probably noth-
ing to be gained by starting allopurinol in the face of
established ARF with anuria.
(4) Agents that inhibit renal excretory mecha-
nisms. In the above examples, the decrease in uric
acid excretion was achieved by inhibition of its pro-
duction and a subsequent fall in its plasma concen-
tration. There is one example of ARF in which renal
damage may be prevented by the direct inhibition of
the tubular secretion of the nephrotoxic agent,
thereby reducing its renal concentration both intra-
cellularly and in the tubular fluid. This involves the
action of probenecid on cephaloridine, and is dis-
cussed elsewhere in this Symposium. This type of
pharmacologic action has not been applied clinical-
ly. Certainly, other less nephrotoxic cephalosporins
are available. It is not known if such an approach
will be clinically applicable.
(5) Agents that chelate heavy metals. Mercuric
chloride poisoning is the classical clinical, as well as
experimental, example of ARF induced by heavy
metals. The kidney is rich in protein-bound sulfhy-
dryl groups, which have a high aThnity for mercury.
Formation of mercury-sulfhydryl complexes leads
to inactivation of essential enzymatic functions and
to cell death. Treatment with a chelating agent such
as dimercaprol may provide almost complete pro-
tection, but immediate therapy is essential. Chelat-
ing agents bind directly with the mercuric ion, thus
either preventing or reversing the binding of the
metal to tissue macromolecules. The effect of such
treatment on intrarenal mechanisms has been well
studied in experimental models [38], The pre-
vention of ARF with poisoning from other heavy
metals is based on a similar rationale, using suitable
chelating agents.
(6) Judicious use of potential nephrotoxins. In
considering the different pharmacologic agents that
may be used in the prevention of ARF, it is perhaps
a truism to observe that drug-induced nephrotoxici-
ty can be prevented by the nonadministration of the
potentially toxic drug. Nevertheless, this is the
point we wish to emphasize. Elsewhere in this Sym-
posium the nephrotoxicity of several drugs is con-
sidered in detail. General surveys are also available
[39]. Two points may be made. First, both the
cholecystographic and urographic radiocontrast
agents are potentially nephrotoxic. Physicians often
erroneously do not consider these agents to be
drugs. Second, many cases of ARF occur in the
clinical setting in which multiple drugs have been
prescribed and in which the possibility of drug-drug
interactions is poorly understood.
Drugs used in treatment of established ARF
In considering the drugs available for the treat-
ment of ARF, in contrast to those used for its pre-
vention, it should be recognized that although many
therapeutic agents may be used for both purposes,
the underlying rationale may be quite different in
the two situations, particularly when ARF is ac-
companied by severe oliguria. There are at least
two general considerations; one involves the action
of the therapeutic agent itself; the other relates to
the physiologic or pathophysiologic situation exist-
ing at the time that the drug is administered. Several
Drugs in acute rena/failure 705
examples will serve as illustrations. First, consider
the use of sodium bicarbonate to prevent the precip-
itation of methotrexate. In this instance, drug action
depends on alkalinization of the glomerular filtrate
as it traverses down the nephron to become tubular
fluid. If intraluminal precipitation had resulted from
the prior precipitation of methotrexate, there would
be no known means by which an alkaline tubular
fluid could gain access to the site at which it would
have to exert its action. In addition, it is probable
that the pH would need to be higher to redissolve
precipitated methotrexate than to keep it in solu-
tion. As a second example, consider a high intake of
sodium chloride, either in the diet or by infusion.
There are several experimental models in which this
regimen decreases the severity of ARF. This ap-
plies to conditions prevailing at the time of the ini-
tial insult, when excretion of salt may appropriately
balance increased intake. But, given the patient
with ARF with anuria, persistent high salt intake
can only lead to expansion of extracellular fluid vol-
ume and pulmonary edema. This, in fact, was a
common complication when ARF was uncritically
treated with saline infusions in the expectation that
such loading might "open up the kidneys." As a
third example, consider renal blood flow. In the
models of ARF produced by glycerol, renal artery
clamping, and intrarenal norepinephrine, there is a
marked initial reduction of renal blood flow. This
produces ischemia. If this is promptly corrected
one may prevent, or at least minimize, further renal
damage. In these same models, however, once ARF
is established, blood flow may be restored to nor-
mal, and at the same time severe impairment of gb-
merular filtration persists [8]. Once renal ischemia
has produced ARF and renal blood flow has re-
turned towards normal, it is unlikely that any agent
given to alter renal hemodynamics will improve re-
nal function.
(1) Angiotensin inhibitors. Goormaghtigh [40] and
Trueta et al [41] suggested in their early studies that
a pressor substance released by the kidney might be
responsible for the reduction in renal blood flow and
the changes in its intrarenal distribution. Since that
time, many experiments evaluating the role of al-
tered renal hemodynamics have been performed.
The principal hypothesis proposed is based on a
tubuloglomerular feedback. Alterations in proximal
tubular function produced by either ischemia or
toxins are considered to change the composition of
the tubular fluid. These changes in composition are
in turn sensed by the distal cells of the macula densa
in such a manner as to activate the renin-angioten-
sin system, which results in renal vasoconstriction.
There are many examples of ARF, both in the labo-
ratory and in clinical medicine, in which renin pro-
duction increases and increased levels of angioten-
sin I and II are detected [42—47]. These changes in
the activity of the renin-angiotensin system, how-
ever, seem to bear little relationship to changes in
renal function, and they do not support the hypoth-
esis that changes in renin-angiotensin activity are
responsible for the maintenance of ARF in man [45-
47]. A number of attempts have been made in ex-
perimental animals [48] to reduce or block the activ-
ity of the renin-angiotensin system with passive or
active immunization, with antagonists to both con-
verting enzyme and to angiotensin II. Although sa-
ralasin (I sarconine-8-alanine-s-isoleucine-angioten-
sin II) can be shown to block some of the intrarenal
hemodynamic effects [48] of angiotensin, it does not
alter experimental ARF. The reduction of renin
stores as a result of sodium chloride loading similar-
ly fails to consistently alter the course of estab-
lished ARF.
In the clinical syndrome of hypertensive crisis
with hyperreninemia and ARF seen in some pa-
tients with scleroderma, preliminary reports [49]
suggest, however, that the angiotensin-converting
enzyme inhibitor captopril may reverse this life-
threatening complication. Although captopril also
promotes the accumulation of the vasodilator bra-
dykinin, it seems likely that in this situation its ma-
jor action depends on the inhibition of the formation
of angiotensin II.
(2) Prostaglandins (PG's). Because PG's are
manufactured within the renal parenchyma (as well
as elswhere) and act on vascular smooth muscle, it
has been suggested that they may play a role in the
regulation of renal blood flow and may be involved
in the hemodynamic disturbances of ARF [50-52].
It seems reasonable to suggest that the use of PG's
to increase renal blood flow, and possibly also GFR,
might ameliorate ARF. Studies with various mod-
els, including norepinephrine and uranyl-nitrate-in-
duced ARF [52] showed that renal vascular resis-
tance could be profoundly reduced by PG's. De-
spite return of renal blood flow towards normal, the
functional impairment (reduced filtration) appeared
to remain unaltered.
Severe renal vasoconstriction is the underlying
cause of the syndrome of ARF associated with he-
patic failure (hepatorenal syndrome). The effects of
infusing PG's are variable. In one study, no im-
provement in renal function was observed, even
when PG's were combined with beta agonists [51].
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In another report, significant improvement in GFR,
renal plasma flow, and sodium excretion was ob-
served [53]. But, the greater the degree of ARF, the
poorer was the response. Caution needs to be used
with the administration of PG's to man with ARF,
as profound hypotension can occur.
There is additional evidence to suggest that PG's
may have a relatively specific role in the mainte-
nance of renal function in patients with liver dis-
ease, in contrast to renal failure of other etiologies.
With the administration of indomethacin, which is
an inhibitor of PG synthesis, there is a prompt re-
duction in renal blood flow, which can be corrected
by the administration of PG's [54]. PG's may also
redistribute the renal blood flow between the super-
ficial and deep cortex [55]. This complex problem is
considered in detail in another paper of this Sym-
posium.
(3) Beta adrenergic blocking agents (/3-blockers).
/3-blockers affect the renin-angiotensin system to
suppress the circulating renin activity [56]. lainia,
Solomon, and Eliahou [57] and others [56, 58, 59]
have shown that /3-blockers will protect against the
development of ARF in experimental animals. This
protection, however, does not appear to be directly
related to renin-angiotensin suppression [59] as nei-
ther saralasin nor immunization against renin pro-
duce similar changes. The effect of propranolol on
renal blood flow may be quite variable [58]. There
are no studies in man that support the use of /3-
blockers to treat established ARF. With the long-
term use of propranolol, renal function may be com-
promised [60], but the frequency of this complica-
tion seems quite variable and its significance re-
mains to be ascertained.
(4) Dopamine. The therapy of shock has been his-
torically associated with the use of sympathomimet-
ic agents. It has become apparent that the use of a-
agonists in shock is associated with a diminished
peripheral circulation and a poor outcome in many
clinical settings, the exceptions being anaphylactic
shock and some instances of cardiogenic shock. /3-
agonists and agents with a mixed a and /3 action
have been used to maintain central blood pressure
without sacrificing peripheral flow [61]. In the last
decade, dopamine [61-63] has been used with in-
creasing frequency in the therapy of shock and as-
sociated ARF. This agent appears to have a direct
action on the renal vasculature. The presence of
specific dopaminergic receptors in the kidney is
considered elsewhere in this Symposium.
When dopamine is administered directly into the
renal artery, the GFR and renal plasma flow are in-
creased unilaterally. Small-scale studies have thus
far not demonstrated any benefit from dopamine
alone in established ARF. Synergistic effects of
dopamine with furosemide have recently been re-
ported in uranyl-nitrate-induced ARF, in which nei-
ther the dopamine nor furosemide, when used
alone, had any effect on GFR [64]. Dopamine has
been used in man in the hepatorenal syndrome with
variable success [65—67], but its exact therapeutic
role awaits further study.
(5) Isoproterenol and epinephrine. These have /3-
agonist actions with overall peripheral vasodilata-
tion, accompanied by an increase in cardiac output.
These agents have a well-established role in the
therapy of shock, but there is no evidence to in-
dicate that they will specifically influence the course
of ARF, except when used experimentally prior to
the production of injury [61].(6) a-Blockers. These have not been shown to
have any particular advantage over /3-agonists or
dopamine, and may be more difficult to handle in
the clinical situation [61].
(7) Acetylcholine and bradykinin. Many vasoac-
tive substances have been implicated in the etiology
of ARF and have been used to induce experimental
ARF or to modify its course. Acetylcholine was ad-
ministered to four patients with ARF of diverse
etiologies [68]. All showed an improvement in total
renal blood flow with a change in its distribution
within the kidney. It is of interest that patients with
interstitial nephritis appeared to have a greater re-
sponse than did those with glomerular disease. Ace-
tyicholine primarily dilates the efferent arterioles,
and as a result, the GFR may not rise, despite an
increase in renal blood flow. Bradykinin has also
been reported to increase renal blood flow in a simi-
lar fashion [69].
(8) Adenosine triphosphate (ATP) and magne-
sium chloride. These agents have been used in ex-
perimental models after ischemic damage has been
inflicted [70]. They produce a more rapid recovery
in cortical blood flow and in glomerular function.
Both ATP and magnesium are known to have po-
tent effects as vasodilators. It is uncertain whether
or not this is the basis for their action in ARF. Osias
et al [70] have proposed that the nucleotide
"primes" the injured cell to allow more rapid syn-
thesis of ATP and thereby to improve cell function.
The clinical role of such agents awaits definite tri-
als.
(9) Glucagon. Glucagon has been used in experi-
mental ARF and has been shown to ameliorate its
severity if administered early, but not once ARF
has become established [71].
(10) Thyroxine. Thyroxine has been used in ARF
in experimental animals and in man [72, 73]. The
basis for this therapy is the hormone's presumed
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ability to stimulate renal tubular transport mecha-
nisms. Thyroxine also stimulates gluconeogenesis
and lipolysis, and this may result in increased activ-
ity of the citric acid cycle. Because of the hor-
mone's many other actions, it seems unlikely that it
will be a practical agent in the clinical management
of ARF.
(11) Antibiotics. Hypotension induced by sepsis
is the most common mechanism by which infections
produce ARF. Infections of the kidney itself, such
as abscesses or suppurative pyelonephritis, may al-
so decrease renal function. In these instances, the
goals of either medical or surgical treatment are
clear-cut and need not be elaborated on further.
Another mechanism must also be recognized.
This is observed in patients with bacterial endo-
carditis, ventricular shunt disease, or visceral ab-
scesses. Glomerular lesions of varying morphology
develop through an immunologic mechanism in re-
sponse to the distant infection and can lead to a type
of ARF that is functionally identical to that seen
from many other causes. Proper management with
antibiotics and/or surgery cures the primary infec-
tion and leads to a reversal of the renal lesion in a
large number of cases [16, 74].
(12) Nutrition. The improved survival of patients
has been reported with early and aggressive mea-
sures designed to prevent tissue catabolism. This
involves parenteral feeding of amino acids and calo-
ries, the latter in the form of carbohydrate and fat
[75]. The importance of diet can be demonstrated
both in man and in experimental animals [76, 77]. It
should be remembered, however, that parenteral
alimentation is not without the risk of infection and
secondary metabolic and physiologic disturbances
[77]. This appears to be the one therapeutic regimen
that benefits patients with ARF, regardless of etiol-
ogy.
(13) Increase in rate of urine flow. In discussing
the prevention of ARF, examples were cited in
which an increased rate of urine flow appeared to be
highly effective. In the treatment of established oh-
guric ARF, attempts are commonly made in order
to increase urine volume. The efficacy of such treat-
ment is highly debatable.
For simplification, three types of agents may be
considered against the background of oliguric ARF:
parenteral intake of saline (or its oral equivalent),
mannitol, and high-ceiling diuretics, for which we
will use furosemide as an example. In the event that
these agents are successful, they have the following
actions in common: increase the rate of urine flow;
dilution of concentration of "toxin" in the tubular
fluid; reduction of obstruction of tubules from cell
debris; prevention of precipitation of "toxin" from
the tubular fluid; and in comparison to the oliguric
state, an increased rate of potassium excretion. In
addition, the increased urine formation may permit
the more liberal administration of fluid and elec-
trolyte in the diet and thereby facilitate practical as-
pects of clinical management.
The same three categories should also be consid-
ered with respect to the differences in their actions.
Some of these may be speculative, because each
factor is not documented in reference to ARF of all
etiologies. As to parenteral saline or oral salt, if
urine flow does not increase, persistent therapy will
lead to expansion of extracellular fluid volume and
eventually pulmonary congestion and edema. Al-
though saline can be considered as a physiologic
"diuretic," its efficacy is abruptly reduced by even
a slight reduction in GFR. Theoretically, saline
would be ineffective if an abnormal increase in tubu-
lar permeability were one of the factors contributing
to oliguria. Unlike the other agents, a high salt in-
take would decrease the intrarenal stores of renin
[78]. This may lead to protection of the kidney in
various experimental models of ARF [8], but it is not
known whether or not this would be an important fac-
tor in the treatment of established ARF [79—8 1].
Mannitol is virtually pharmacologically inert in
the usual sense, and owes its action to its osmotic
effects. It is distributed in the extracellular fluid, not
metabolized, filtered at the glomerulus, and not
reabsorbed by the normal renal tubule. The admin-
istration of mannitol results in renal vasodilatation,
and the production of renin may be acutely reduced
[82]. As a diuretic, mannitol is effective in the face
of a greatly reduced GFR [83]. Theoretically, it
would become ineffective as a diuretic if tubular
permeability were abnormally increased. The ef-
fectiveness of mannitol to increase urine flow
largely depends on its own excretion. Thus, when
urine flow does not increase, the persistent adminis-
tration of mannitol expands extracellular fluid vol-
ume in the same manner as excessive saline. Anoth-
er quasi-specific action of mannitol was at one time
proposed in relation to the pathogenesis of ARF.
This involved the fact that ischemic cells increase in
volume, and that this change in volume can be re-
versed by the high concentration of an obligatory
extracellular solute such as mannitol. If such swel-
ling were to involve the cells of the renal micro-
vasculature, it would provide a mechanism by
which ischemia could perpetuate itself. Although
such a mechanism seems quite logical, more recent
studies have failed to implicate it in the pathogene-
sis of ARF [83]. There is probably no rationale for
the administration of mannitol in ARF with this the-
oretical mechanism in mind.
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Furosemide acts directly on renal tubular trans-
port and is administered in doses that are os-
motically insignificant. Thus, if it fails to produce a
diuresis or fails to be excreted, this, in itself, does
not lead to an expansion of extracellular fluid vol-
ume. From this point of view, drugs such as furose-
mide have an advantage over saline or mannitol.
Many diuretics that act directly on renal tubular
transport of electrolytes lose their effectiveness
when GFR is reduced. In this situation, the results
with furosemide are quite unpredictable. Some-
times the drug is an effective diuretic, other times
not. The action of furosemide on renal blood flow is
also variable. It is a renal vasodilator, but it also
increases the renal release of renin [78]. Under
some circumstances, furosemide increases the
nephrotoxicity of other drugs, such as amino-
glycosides. It is difficult to evaluate the significance
of this in relation to available clinical data. On the
basis of scattered case reports, the hearing loss in-
duced by furosemide may be accentuated by ARF.
There is no doubt but that the high ceiling diuretics
(furosemide, ethacrynic acid, and bumetanide) can
increase the output of urine in many patients with
ARF. Nevertheless, the role of these drugs in the
therapy of established ARF remains unclear [84-
90]. Clinical studies show that although the output
of fluid and solute increases in some patients, there
is no change in filtration rate or renal blood flow
[85]. The evidence at this time indicates that these
agents do not alter the course of established ARF in
man.
There is considerable disagreement as to what ex-
tent it is worthwhile to attempt to increase the rate
of urine flow in established ARF. It is also held by
some, but not by others, that in the border between
early ARF and established ARF, there is an inter-
mediate phase of renal function that can be favor-
ably influenced by diuretic therapy as judged by fi-
nal outcome [23, 24]. Common sense dictates that if
an attempt to increase the rate of urine flow is un-
successful, it should be abandoned promptly, rather
than pursued to the point of almost inevitable tox-
icity.
(14) Heparin and antiplatelet drugs. Although in
a number of situations, both in man and in experi-
mental animals, there is evidence of vascular occlu-
sion or of damage to kidney tissue associated with
intravascular coagulation or deposition of fibrin [33,
91—93], there is as yet no evidence to suggest that
anticoagulants are of value in the treatment of es-
tablished ARF that results either from ischemia or
nephrotoxins.
(15) Antiinflamma tory and immunosuppressive
agents. Along with the anticoagulants, drugs of
these two classes are undergoing a number of clini-
cal trials for the treatment of several forms of gb-
merulonephritis [94]. By some criteria, these dis-
eases might be included as a form of ARF, but when
considered in relation to both etiology and to their
subacute to chronic nature, they constitute a clearly
separate category, which is beyond the scope of this
review.
Summary. ARF has been considered in terms of
the acute impairment of renal function. By defini-
tion, this excludes those diseases of the kidney in
which renal functions are but slightly impaired, as
well as those that are chronic in nature.
From many points of view, it is essential (1) to
distinguish between those therapeutic measures
that are directed to the general well being of the pa-
tient and those specifically directed to the renal dis-
order; (2) to distinguish between those measures
that are effective in preventing ARF and those that
may be used in the treatment of the disorder once it
is firmly established; and (3) to evaluate therapeutic
efficacy in relation to specific etiology, rather than
in reference to general patterns of disease.
In the case of prevention, depending on the puta-
tive cause, a finite number of procedures are both
rational and effective. As to the treatment of estab-
lished ARF, many of the underlying patho-
physiologic mechanisms appear not to be influ-
enced by pharmacologic intervention. It is impor-
tant to qualify such a generalization when
considering specific etiologic categories. Of the gen-
eral therapeutic measures that are applicable to dis-
ease regardless of cause, adequate and proper nutri-
tion warrants the greatest attention.
Reprint requests to Dr. D. J. Tiller, Renal Unit, Royal Prince
Alfred Hospital, Missenden Road, Camperdown 2050 N.S. W.,
Australia
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